John MaraganoreFounder

United States - Boston, Massachusetts

John was born in Chicago, Illinois, U.S. in 1962 to Greek immigrant parents. He has a B.A. (1984), M.S. (1985), and Ph.D. (1986) from the University of Chicago in the Division of Biological Sciences. Maraganore started his career as a post-doctoral research scientist at Upjohn from 1985-86. From 1986-87, he was a senior scientist at Zymogenetics. From 1987-1997, he was at Biogen in Cambridge, Massachusetts. At Biogen, he invented bivalirudin, a direct-acting thrombin inhibitor, later commercialized in the U.S. as ANGIOMAXTM. In 1997, Maraganore joined Millennium Pharmaceuticals in a number of senior leadership roles.From 2002-2021, John served as the founding CEO and a Director at Alnylam Pharmaceuticals. At Alnylam, he led the company’s pioneering efforts to advance RNA interference therapeutics, bringing 5 approved products to market and building $25 billion in market capitalization. On 12/31/21, John transitioned CEO leadership of Alnylam to Yvonne Greenstreet. Maraganore was Chair of the Biotechnology Innovation Organization (BIO) from 2017-2019 and currently serves as Chair Emeritus and a member of the BIO board. John is the principal of JMM Innovation LLC, focused on advancing transformative medicines to patients through investment and Board and strategic advisory roles. He serves as a Venture Partner or Advisor to investment firms including Arch Venture Partners, Atlas Ventures, Blackstone, Jeffries, and RTW Investments. He is on the Board of a number of public companies: Beam Therapeutics, Kymera Therapeutics, Rapport Therapeutics, and Takeda Pharmaceuticals. John is also on the Board of a number of private companies: Aera Therapeutics (Chair), City Therapeutics (Exec Chair), Corsera Health (co-CEO), Gemma Biotherapeutics, Merida Biosciences, and Hemab Therapeutics (Chair), in addition to other emerging companies. He is an active mentor to emerging leaders across the biotechnology industry and also serves in strategic advisory roles for a number of innovative biotechnology companies. Maraganore is active with a number of non-profit organizations committed to the development of future life sciences leaders and to the advancement of innovative medicines for patients. He serves on a number of non-profit Boards or Advisory Boards, including: Termeer Foundation, Nucleate, n-Lorem, Ariadne Labs, CHDI Foundation, and MGH Research Institute.